Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies ; volume:8 ; number:1 ; day:20 ; month:12 ; year:2022 ; pages:1-7 ; date:12.2022
npj Breast cancer ; 8, Heft 1 (20.12.2022), 1-7, 12.2022
- Urheber
-
Mouabbi, Jason A.
Raghavendra, Akshara Singareeka
Bassett, Roland L.
Hassan, Amy
Tripathy, Debu
Layman, Rachel M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-022-00499-7
- URN
-
urn:nbn:de:101:1-2023030221070549298990
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mouabbi, Jason A.
- Raghavendra, Akshara Singareeka
- Bassett, Roland L.
- Hassan, Amy
- Tripathy, Debu
- Layman, Rachel M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer